The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study.

What Was Tested

The paper reports a study of Angiotensin II Type 1 Receptor Blockers, published as a randomized controlled trial.

The researchers planned the INNOVATION study to determine whether telmisartan, an angiotensin-2-receptor blocker, delays the progression of renal disease from incipient nephropathy to overt nephropathy in hypertensive or normotensive Japanese patients with type 2 diabetes mellitus.

Why It Was Studied

The INNOVATION study is a randomized, double-blind, placebo-controlled trial.

Patients who need treatment with angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors are excluded.

Who Took Part

The abstract describes 1855 patients taking part.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Angiotensin II Type 1 Receptor Blockers study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the patients and researchers unaware of who received Angiotensin II Type 1 Receptor Blockers.

The comparison arm used a placebo, so changes seen with Angiotensin II Type 1 Receptor Blockers could be set against what happens without it.

What Was Measured

PubMed files the paper under topics including Albuminuria, Angiotensin II Type 1 Receptor Blockers, Benzimidazoles, Benzoates, Blood Pressure, Creatinine and Diabetes Mellitus, Type 2.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II Type 1 Receptor Blockers in 1855 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2006 (The Journal of international medical research), a journal based in England.

More context: all human trials.